Prana Biotechnology Ltd. (NASDAQ:PRAN) shares fell 8% during mid-day trading on Wednesday . The stock traded as low as $5.47 and last traded at $5.50, with a volume of 80,344 shares changing hands. The stock had previously closed at $5.98.

Separately, Zacks Investment Research upgraded shares of Prana Biotechnology from a “sell” rating to a “hold” rating in a report on Friday, June 24th.

The company’s 50 day moving average is $4.70 and its 200-day moving average is $3.82. The firm’s market capitalization is $7.98 million.

Prana Biotechnology Limited (Prana) is an Australia-based development stage medical biotechnology Company. The Company is engaged in commercializing research into Alzheimer’s disease, Huntington disease and other major age-related degenerative disorders. The Company’s lead drug candidate, PBT2 is being developed for the treatment of Alzheimer’s and Huntington’s diseases.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.